Search Result

Isoforms Recommended:	CDK2

Results for "

CDK2/cyclin A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (84) Akt (2) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (19) Aurora Kinase (1) Autophagy (4) Bacterial (1) Bcl-2 Family (1) Carbonic Anhydrase (2) Caspase (3) CFTR (1) CXCR (2) DNA/RNA Synthesis (2) Endogenous Metabolite (1) Enterovirus (1) ERK (2) FGFR (1) FLT3 (2) GSK-3 (12) JAK (2) JNK (1) Keap1-Nrf2 (2) MEK (2) Molecular Glues (5) P-glycoprotein (1) Parasite (1) PARP (1) PDGFR (1) PKA (1) PKC (4) PROTACs (3) PSMA (2) Reactive Oxygen Species (ROS) (3) Reference Standards (4) SARS-CoV (1) Ser/Thr Kinase (1) Sirtuin (1) STAT (2) VEGFR (3)
By Research Areas:	Cancer (85) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (10)

By Targets:

CDK (84)

Akt (2)

Androgen Receptor (2)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (19)

Aurora Kinase (1)

Autophagy (4)

Bacterial (1)

Bcl-2 Family (1)

Carbonic Anhydrase (2)

Caspase (3)

CFTR (1)

CXCR (2)

DNA/RNA Synthesis (2)

Endogenous Metabolite (1)

Enterovirus (1)

ERK (2)

FGFR (1)

FLT3 (2)

GSK-3 (12)

JAK (2)

JNK (1)

Keap1-Nrf2 (2)

MEK (2)

Molecular Glues (5)

P-glycoprotein (1)

Parasite (1)

PARP (1)

PDGFR (1)

PKA (1)

PKC (4)

PROTACs (3)

PSMA (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (4)

SARS-CoV (1)

Ser/Thr Kinase (1)

Sirtuin (1)

STAT (2)

VEGFR (3)

By Research Areas:

Cancer (85)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Cyclin G-associated Kinase (GAK) CDK CDKL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108359

Alsterpaullone 1 Publications Verification 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent *CDK* inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and *CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis* in leukemia cell line .

HY-18299

Purvalanol B 1 Publications Verification NG 95	CDK Parasite	Infection Cancer
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor *CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin* B, CDK2-cyclin A, CDK2-cyclin E and *CDK5-p35, respectively. Purvalanol B shows selectivity for CDK* over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include *CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin* A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-170897

CDK2-IN-40	CDK	Cancer
CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits *CDK2*/Cyclin E1 with an IC₅₀ of ≤ 10 nM .

HY-117535

CDK2-IN-4 3 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent *CDK2* inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-173203

CDK2-IN-43	CDK	Cancer
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC₅₀ value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field .

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P3731

Cdk2/Cyclin Inhibitory Peptide II	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-E70674

CDK2/CycO Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-123045

PNU-292137	CDK	Cancer
PNU-292137 is an orally active, potent *CDK2* inhibitor with IC₅₀s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .

HY-170442

CDK2-IN-37	CDK	Cancer
CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase *(CDK2)* inhibitor with anti-cancer activity .

HY-18299A

Purvalanol A 2 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent *CDK* inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-E70673

CDK2/CycE2 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70672

CDK2/CycE1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70671

CDK2/CycD1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70669

CDK2/CycA1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70670

CDK2/CycA2 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-168057

PROTAC CDK2 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for **cyclin-dependent kinase 2 (CDK2)*. PROTAC CDK2* Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀ of 100-500 nM .

HY-18299AR

Purvalanol A (Standard)	CDK Autophagy Apoptosis	Cancer
Purvalanol A (Standard) is the analytical standard of Purvalanol A. This product is intended for research and analytical applications. Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a **cyclin-dependent kinase (CDK) inhibitor, with IC₅₀** values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .

HY-15004

AUZ 454 5 Publications Verification K03861	CDK	Cancer
AUZ 454 (K03861) is a type II *CDK2* inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

HY-173310

CDK2-IN-44	CDK	Cancer
CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective *CDK* inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .

HY-12529

Ro-3306 Maximum Cited Publications 56 Publications Verification	CDK Apoptosis	Cancer
Ro-3306 is a potent and selective inhibitor of *CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin* B1 and CDK2/cyclin E, respectively.

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent *CDK1* and *CDK2* inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively .

HY-173124

CDK2/FLT4/PDGFRA-IN-1	CDK VEGFR PDGFR Apoptosis	Cancer
CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC₅₀s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells .

HY-12302

Kenpaullone 5+ Cited Publications 9-Bromopaullone; NSC-664704	CDK GSK-3	Cancer
Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC₅₀s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC₅₀s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of *CDK* and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-162270

CDK2-IN-24	CDK	Cancer
CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective *CDK* inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM) .

HY-W011428

Olomoucine	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of *CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin* B, Cdk2/cyclin A, Cdk2/cyclin E (both IC₅₀=7 μM), CDK/p35 kinase (IC₅₀=3 μM) and ERK1/p44 MAP kinase (IC₅₀=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-W011428R

Olomoucine (Standard)	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-160941

CDK2-IN-29	CDK	Cancer
CDK2-IN-29 (Compound 13q) is an inhibitor for cyclin-dependent kinase (CDK), with IC₅₀ of 96 nM and 360 nM, for *CDK 2* and CDK 4, respectively .

HY-N6953

Garcinone D 3 Publications Verification	STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)	Neurological Disease
Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-10014

R547 2 Publications Verification	CDK GSK-3 Apoptosis	Cancer
R547 is a potent, selective and orally active ATP-competitive *CDK* inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-111260

R547 mesylate	CDK GSK-3 Apoptosis	Cancer
R547 mesylate is a potent, selective and orally active ATP-competitive *CDK* inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .

HY-10424R

Milciclib (Standard) PHA-848125 (Standard)	Reference Standards CDK Autophagy	Cancer
Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-161776

P-gp/CDK2-IN-1	P-glycoprotein CDK	Cancer
P-gp/CDK2-IN-1 (Compound 4j) is an inhibitor for is inhibitor for P-glycoprotein (P-gp) and for cyclin-dependent kinase-2 (CDK2). P-gp/CDK2-IN-1 inhibits the proliferation of cancer cells SW-480 and MCF-7 wit IC₅₀ of 38.6 μM and 26.6 μM. P-gp/CDK2-IN-1 exhibits antioxidant efficacy with EC₅₀ of 580 μM in DPPH experiment .

HY-15612

CDK4-IN-1	CDK	Cancer
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

HY-N6953R

Garcinone D (Standard)	Reference Standards STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)	Neurological Disease
Garcinone D (Standard) is the analytical standard of Garcinone D (HY-N6953). This product is intended for research and analytical applications. Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-111361

FN-1501 2 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and *CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin* A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-18340

(R)-CR8 CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8, a second-generation analog of Roscovitine, is a potent *CDK1/2/5/7/9* inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-137894A

Tagtociclib hydrate PF-07104091 hydrate	CDK GSK-3	Cancer
PF-07104091 hydrate is a potent and selective CDK2/cyclin E₁ and GSK3β inhibitor, with K_is of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E₁-amplified cancers. (patent WO2020157652A2).

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .

HY-170507

CDK-IN-16	CDK	Cancer
CDK-IN-16 (Compound 5g) is a CDK2/cyclin A2 inhibitor with an IC₅₀ of 1.67 μM. CDK-IN-16 exhibits anticancer activity. The IC₅₀ of CDK-IN-16 against the AGS cell line is 3.5 μM .

HY-18340A

(R)-CR8 trihydrochloride CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent *CDK1/2/5/7/9* inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .

HY-112450

Olomoucine II	CDK	Cancer
Olomoucine II is a potent *CDK* inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .

HY-108348

BML-259	CDK	Neurological Disease
BML-259 is a potent cyclin-dependent kinase 5 *(Cdk5)* inhibitor, with IC₅₀s of 64 and 98 nM for Cdk5 and Cdk2, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P10324

TAT-p16 p16^INK4a peptide	Peptides	Cancer
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6953

Garcinone D 3 Publications Verification	Xanthones Guttiferae Source classification Phenols Polyphenols Garcinia mangostana Linn. Plants	STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)
Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-N3389

Licoisoflavone A 1 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the *CDK2-Cyclin* E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-18981

Decursin 1 Publications Verification (+)-Decursin	Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-W019806

Lacto-N-fucopentaose I LNFP I	Infection Natural Products Polysaccharides Classification of Application Fields Animals Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite CDK Reactive Oxygen Species (ROS) Apoptosis Enterovirus Bacterial
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote *CDK2* and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .

HY-N7045

Isosilybin B 2 Publications Verification	Flavanonols Flavonoids Glycine soya Classification of Application Fields Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Disease Research Fields Cancer	Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce *cyclins* (D3, D1, A, E), *Cdk4, Cdk2, Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-N6953R

Garcinone D (Standard)	Xanthones Guttiferae Source classification Phenols Polyphenols Garcinia mangostana Linn. Plants	Reference Standards STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)
Garcinone D (Standard) is the analytical standard of Garcinone D (HY-N6953). This product is intended for research and analytical applications. Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-18981R

Decursin (Standard) (+)-Decursin (Standard)	Source classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC.	Reference Standards PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

HY-N7045R

Isosilybin B (Standard)	Flavanonols Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Reference Standards Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce *cyclins* (D3, D1, A, E), *Cdk4, Cdk2, Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

Cat. No.	Product Name	Chemical Structure

HY-P10324

TAT-p16
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81587

	SKP2 Antibody (YA1332) SKP2; FBXL1; S-phase kinase-associated protein 2; cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	SKP2 Antibody (YA1332) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SKP2.

HY-P85367

	SKP2 Antibody (YA5059) SKP2; FBXL1; S-phase kinase-associated protein 2; cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2	WB, IHC-P	Mouse, Rat
	SKP2 Antibody (YA5059) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SKP2.

HY-P82229

	SKP1 Antibody (YA1974) SKP1; EMC19; OCP2; SKP1A; TCEB1L; S-phase kinase-associated protein 1; cyclin-A/CDK2-associated protein p19; Organ of Corti protein 2; OCP-2; Organ of Corti protein II; OCP-II; RNA polymerase II elongation factor-like protein; SIII; Transcr	WB, ICC/IF	Human, Mouse, Rat
	SKP1 Antibody (YA1974) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SKP1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks